Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

Dapoxetine india is an fda approved medication and it is the only treatment for erectile dysfunction and also an efficient remedy for men who are not sexually excited enough for a normal sex life. Pregnancy can also trigger other medical problems azithromycin prescribed for Kenilworth such as high blood pressure and gestational diabetes. Clomid and nolvadex for sale in usa of clomid and nolvadex for sale in usa.

I have visited several doctors and tried many different things to alleviate my pains. In the next part, we’re going to show you how to edit your blog posts and how http://served.ngo/ to publish and manage your blog posts. We offer free telephone, email and live chat support 24 hours a day, 7 days a week.

Get the best prices for all your drugs and medicines, no matter where you order from. The flovent inhaler prices standard dose is 50mg/5ml daily or 200mg/5ml every other day. It predicts a further slowdown with the euro zone in recession and the u.s.

More info about license types

Free of 21 % VAT (except in Spain and also in the European Union without valid intl. VAT no), delivery costs do not apply.

You can also order this product via email or fax, please download the Order Form

Publisher: La Merie Publishing
Pages: 32
Format: PDF
Product Line: Brief Report
Product Code: LMBR0017
Release Date: May of 2022
Loading...

Cadherins are a family of glycoproteins responsible for calcium ion–dependent cell adhesion. There are more than 100 types of cadherins in humans, and many of them are not only responsible for cell adhesion but also involved in tumorigenesis. Cadherin 17 (CDH17), also known as human liver intestine–cadherin (LI-cadherin), or intestinal human peptide transporter-1 (HPT-1), is a non-classical cadherin composed of an ectodomain consisting of seven extracellular cadherin (EC) repeats, a single transmembrane domain, and a short cytoplasmic domain.

CDH17 is a highly specific marker of gastrointestinal epithelium; most gastrointestinal adenocarcinomas are CDH17-positive with strong membranous staining. However, healthy tissue colonic mucosa and duodenal mucosa also are positive for CDH17 which prevented consideration of CDH17 as an ideal tumor associated antigen for development of CDH17-targeted therapies.

It was only very recently, that investigators discovered that CDH17 is masked in healthy tissue and is not attacked by large molecules or cells. Thus, CDH17 represents a class of previously unappreciated tumor-associated antigens that is ‘masked’ in healthy tissues from attack by CAR T cells for developing safer cancer immunotherapy.

This report describes and analyzes as of May 2022

  • The scientific rationale for CDH17-targeted therapies based on target characteristics and its differential expression profile;
  • Preclinical proof-of-concept of CDH17-targeted different drug modalities;
  • Clinical indications suitable for development of CDH17-targeted therapies and their patient populations;
  • The competitive landscape of CDH17-targeted drug modalities in development;
  • Specific profiles of CDH17-targeted drug modalities; and
  • Profiles of companies active in the development of anti-CDH17 therapy candidates.

Effector-enhanced antibodies and cells such as antibody-drug conjugates, chimeric antigen receptor (CAR) T-cells, and bispecific antibodies redirecting T-cells or specifically activating T-cells will be enabled by and benefit from the cancer “selective” expression profile to avoid on-target, off-tumor toxicity.

CDH17 provides a great opportunity for drug discovery and development as the competitive landscape still is very favorable for new entrants, but the first molecules have entered clinical development.

Table of Contents

1          Target Background

2          Target Antigen Expression Profile

3          Preclinical Proof-of-Concept

4          Clinical Indications & Patient Populations

5          Competitive Landscape & Drug Modalities

6          Drug & Cell Therapy Candidate Profiles

6.1       CAR T-Cells

6.2       Pro-Apoptotic Bispecific Antibodies

6.3       T-Cell Redirecting Bispecific Antibodies

6.4       Naked Antibodies

7          Company Profiles

8          References

Single User License:

This license allows for use of a report by one named person, explicitly confirmed at point of sale

Departmental License:

This license allows for use of a report by members of the same Dept within the same enterprise location or of the same international Project Group.

Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise location.

Global Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise worldwide.

Contacts

Custom Support & Sale:

Mon–Fri: 10:00 am –5:00 pm GMT+01